NLS Pharmaceutics Amends Merger Agreement for Fourth Time
Ticker: NCEL · Form: 6-K · Filed: Jun 6, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, amendment, agreement
TL;DR
NLS Pharmaceutics amended its merger deal with Kadimastem AGAIN on June 5th. Fourth time's the charm?
AI Summary
On June 5, 2025, NLS Pharmaceutics Ltd. entered into a fourth amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This amendment modifies the original merger agreement dated November 4, 2024, which has seen previous amendments on January 30, February 17, and May 5, 2025.
Why It Matters
This repeated amendment to the merger agreement suggests ongoing negotiations or adjustments to the terms, which could impact the timeline and finalization of the merger between NLS Pharmaceutics and Kadimastem.
Risk Assessment
Risk Level: medium — Frequent amendments to a merger agreement can indicate potential complexities or disagreements, increasing the risk of the deal not closing as planned.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant and party to merger agreement
- Kadimastem Ltd. (company) — Party to merger agreement
- NLS Pharmaceutics (Israel) Ltd. (company) — Party to merger agreement
- June 5, 2025 (date) — Date of the fourth amendment
- November 4, 2024 (date) — Original merger agreement date
FAQ
What specific terms were changed in the fourth amendment to the Merger Agreement?
The filing does not specify the exact terms that were altered in the fourth amendment, only that an amendment was entered into.
What is the primary purpose of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd.?
The filing does not explicitly state the primary purpose of the merger, but it is an Agreement and Plan of Merger.
When was the original Agreement and Plan of Merger signed?
The original Agreement and Plan of Merger was signed on November 4, 2024.
How many previous amendments have been made to the Merger Agreement before this fourth amendment?
There were three previous amendments made to the Merger Agreement before the fourth amendment: on January 30, 2025, February 17, 2025, and May 5, 2025.
Is NLS Pharmaceutics Ltd. required to file annual reports on Form 20-F?
Yes, NLS Pharmaceutics Ltd. indicates by check mark that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 6, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).